Vertex Pharmaceuticals confirmed Tuesday the next generation of cystic fibrosis drugs from its research labs will begin mid-stage clinical trials by the end of the year.
Vertex is developing these drugs, VX-440 and VX-152, to become components of new combination regimens to treat the underlying cause of cystic fibrosis.
The company’s hope is the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
